Metraipolis › archive › dc_05dea48a2020
HIF-2α inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies — Europe PMC PMID:41451091
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41451091
- DOI
- 10.3389/fmed.2025.1735808
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T18:18:00.209Z
- SHA-256 of the archived text
5bcae5bc357c0152593ea91690bebfded6fdc9faf0497b05fa6cbc9562311c75- Stable URL of this page
https://metraipolis.com/documento/dc_05dea48a2020
How to cite
HIF-2α inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies — Europe PMC PMID:41451091 — Europe PMC (en), https://europepmc.org/article/MED/41451091 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_05dea48a2020 (Metraipolis archive dc_05dea48a2020, sha256 5bcae5bc357c0152593ea91690bebfded6fdc9faf0497b05fa6cbc9562311c75)
BibTeX
@misc{dc05dea48a2020,
title = {HIF-2α inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies — Europe PMC PMID:41451091},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41451091},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_05dea48a2020; sha256 5bcae5bc357c0152593ea91690bebfded6fdc9faf0497b05fa6cbc9562311c75},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41451091. Agents can read the archived copy with the MCP tool read_document.